Area:
Immunology, Genetics, Molecular Biology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Yasser A. Aldhamen is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2016 — 2017 |
Aldhamen, Yasser |
R21Activity Code Description: To encourage the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) |
Novel Immunomodulating Therapeutics For Hiv-1 Treatment @ Michigan State University
? DESCRIPTION (provided by applicant): The overall objective of this proposal is to investigate the impact of CRACC upregulation on CD4+ and CD8+ T cells of HAART-treated HIV-1-infected patients and develop a novel CRACC-targeting immunotherapeutic strategy aimed to restore T cell functions in HIV-1 patients. HAART for the treatment of HIV-1 infection sustains viral suppression and increases CD4 count, however, it fails to completely control viral replication and reservoirs as well as CD4+ T cell recovery in 10-25% of HIV-1 patients, indicating a critical need for the development of novel therapies that control HIV-1 viral replication and eliminate persistent viruses. Vaccine efforts to combat HIV-1 infection have been limited in efficacy, as such there is not a vaccine approved for use against HIV-1 to date. It has been proposed that blockade of T cell immune checkpoints in HIV-1 patients may restore the regulatory and effector functions of HIV-1-specific T cells; however recent data indicate the need for utilizing novel combinatorial strategies to completely control HIV-1 virus. The proposed innovative strategy utilizes a novel immune modulatory protein that targets a unique signaling pathway in T cells. This approach focuses on stimulating HIV-1-specific T proliferation and cytokine production by modulating the inhibitory activity of the CD2-like receptor activating cytotoxic cells (CRACC) receptor in T cells of HIV-1- infected patients. As a result, enhanced reactivation of latent HIV-1 in CD4+ T cells may occur, thus result in better control of HIV-1 virus. We found in our preliminary data a strong inverse correlation between CRACC expression on CD4+ and CD8+ T cells and CD4+ T cells recovery in HAART-treated HIV-1 infected patients. In addition, in a manner similar to activating other T cell inhibitory receptors, activating CRACC signaling in T cells inhibited T cell degranulation. Furthermore, in an in vivo translation approach, we found that co-administration of a murine CRACC-targeting Fc fusion protein (mCRACC-Fc) and HIV-1/Gag-expressing vaccine improved the magnitude and the breadth of vaccine-induced HIV-1/Gag-specific T cell immune responses. Achievement of this project's goals will increase our understanding about HIV-1- associated immune dysregulation and will lead to efficacious new therapies for HIV-1 that can be translated to clinical applications. Finally, successful development of this immunotherapeutic could also establish a new line of investigation about a potential role for CRACC signaling in other chronic inflammatory conditions, including various infectious diseases and cancers.
|
0.915 |